Christian Hock
Chief Executive Officer
Replay available
HUTCHMED (China) (HKEX:13) Q4 2021 earnings call, held 2020-03-03. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/hutchmed-china-limited-hcm-q4-2021-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Ladies and gentlemen, welcome to Hachmet Company Update. I will now hand the session to Mr. Christian Hock, CEO of Hachmet, to begin today's presentation. Mr. Hock, please.
0:13 Thank you very much, Anika. Welcome, everybody, to the 2021 Full Year Results and Business Update presentation today. Today we put out two announcements, the first being our 2021 full-year results, which we want to spend the vast majority of our discussion today covering. The second was an announcement that's just gone out detailing my retirement as CEO from HutchMed and the appointment of Dr. Weiguo Su As many of you will know, I've been in China for the last 27 years, and I've been the CEO of HutchMed effectively for 22 years.
0:58 It's been a long journey, and it's been a great journey for us all, and the company from its Thank you very much. Three young sons all went to boarding schools in the UK.
1:53 My wife had to move to be close to them. And I found myself in Hong Kong all alone. And with my young family as well as our parents getting older, my wife and I decided that it was time for us to move back to Europe. About five months ago, I informed the board and the nominations committee of this desire. We went through a very detailed and diligent succession process, which was already underway for some time anyway. And we concluded after looking at external and internal candidates and also asking the question, you know, could I remain CEO based out of Europe? We concluded that But the best way forward for the business was to appoint Dr.
2:41 Weiguo Su as the next CEO of ArchMed. I am fully supportive of this. I think it's a great thing for the business. And Weiguo, obviously many of you are aware of Weiguo and his remarkable history and track record. It's a personal decision. It's a tough one for me because it's been a long journey that we've been on. But I have great confidence in the future of the company, the organization, the board, and our shareholders. And I just want to say thank you to everybody for the support that's been given to me and the company through these years. And I really look forward to seeing great things coming from Weiguo and the team.
3:30 Leaving it at that, I would like to move now on to the corporate presentation. I'm sure we can answer any Q&A at the end, but hopefully I think we will all understand that the reasons for this move are purely based on my family responsibilities. So on page three, you can see, sorry, if you could go back to page three, please. The agenda, please, thank you. So I'll touch on some quick opening remarks. Then we have Chen Hong, or Hong Chen, as is the convention in China, to talk about our Senior Vice President of Commercial in China to talk about our commercial results in oncology. Then Weiguo and Marek Kania will talk about our discovery and development programs.
4:21 Our CFO, Johnny Cheng, will talk about the financial status and our Chief Operating Officer, Dr. Karen Atkin will talk about operations and business development. And finally, Weiguo will lay out the upcoming events and the final closing remarks and then we'll go into Q&A. So next slide, please. So HutchMed has built just a fantastic The organization now is over 4,600 personnel across the group. We have a team of 1,500 people in oncology and immunology. We have a genuinely world-class global novel drug discovery organization and manufacturing operation in China. You can see that over those 20 years led by Weiguo and the team, we have created 12 innovative small molecule drug candidates. We built our team on the innovation side to over 800 integrated R&B staff. There are a few oncology and immunology teams of that scale anywhere.
5:44 and, you know, gives us enormous capability. In the pink box, obviously led by Weiguo but also by Marek in the rest of the world, the United States, Europe and Japan, we've built up great clinical development and regulatory operations. We're currently running over 45 clinical studies around the world. And our first three novel drugs, our novel oncology drugs have all been approved. and are now closer to approval outside of China. So, you know, creating the innovation in the blue box and bringing it to patients in the pink box. Now, on the right-hand side, you can see we've been investing greatly over the last three years in our commercial infrastructure. Led by Chen Hong, we now have a team at the end of last year with 630 people.
6:38 Actually, now it's closer to 750 people. on the ground in China, covering all the main oncology hospitals in China. And Chen Hong will take you through the results of last year and the very encouraging unaudited revenue results of the first two months of this year, which we've included in this presentation because of their importance. We've also built, under Marek and our commercial head in the US, Tom Held, A terrific group of people in the U.S. in commercial and medical affairs that now numbers over 50 people already for the launch of our first product in 2022.
7:23 So next slide, please. 2021 was an exceptional year. You know, it was extremely hard work by everybody on this call. And we just achieved some fantastic things. I put them into three buckets. On the commercial side, commercial results in China Oncology with the two launches to land on all pathways, building the team up to 630 people, and then commercial results that Chen Hong will explain in a bit more detail later, but terrific progress commercially. The clinical portfolio really enjoyed step change progress. We are running 13 registration studies and another five plus Thank you very much.
8:36 A major data presentation. A number of new assets have been put into the clinic and a good deal with Epizyme on Tadveric. So a lot of progress on the portfolio. And the last box is the global ambition. I mean, one of the things that differentiates Hachmed from any China biotech is that we don't see ourselves as a China biotech. We see ourselves as a biotech company that's bringing homegrown Chinese innovation to the global market. So that's Development Organization, clinical regulatory team in New Jersey and in Europe of now 130 or so people is allowing us to do that. We've got seven assets in clinical trials outside of China.
9:21 Frequentinib's just completed its global phase three, the FRESCO study, so we're getting hopefully a readout of that middle of this year, which will be an enormous step for Frequentinib. Surofatinib, the USNDA, and European MAA are filed and under review and in the very late stages of those processes. And we're getting ready for the launch of the second half of the year on Suro. So, you know, 2021 has just been a great year for us all and we've positioned ourselves very well for 22. Next slide, please. So I'll stop there and hand it over to Chen Hong to talk about the progress in commercial so far this year and last year. Over to you, Chen Hong.
10:11 Thank you, Christian. Next slide, please. HatchMED started the on-the-ground promotion activities for annulates in Q4 2020. So 2021 was the first full year for HatchMED to commercialize its innovative products both Annulate and Solenda through its own commercialization platform. The first slide shows ParchMed commercialization capabilities in terms of team size, hospital pharmacy listing, hospital and city coverage. We can see that the team size increased to 630 by the end of 2021 and will continue to expand along with the business growth.
10:57 The growth for hospital pharmacy listing hospital and the city coverage were 131%, 73% and 42% respectively, comparing with the end of September 2020. Next slide, please. This slide shows the market performance of Annulate. Annulate achieved the 71 million US dollars in market sales in 2021. with 111% growth versus 2020. More than 22,000 third-line CRC new patients were treated with Annulate in 2021. Around 4,800 educational events were executed in 2021 for Annulate. According to the post-launch checking study implemented by Acribia, Annulate achieved shared leadership by exceeding Sivaga.
11:56 which was launched two years earlier with annually capturing 39% of patient share in Q4 last year. And it successfully passed the NRDR review last year with only 5% price cut versus the 2021 NRDR price. From the generally treated patient comparison and audited, the first two month sales of 2022 We can see analytics continues to keep very fast growth. Next slide, please. This slide shows the market performance of Solenda. Solenda was launched in January 2021 and achieved $11.6 million in market sales for the first year.
12:48 About 4,800 patients were treated by Solenda and more than 12,000 HCPs for involving Zolanda academic events in 2021. Comparing with the average 64% price cut across all oncology NRDL products, we were successful with Zolanda entering to the NRDL with a 52% price cut. We can see the treated patient number in January this year, which was Zolanda's first month for reimbursement. was seven-fold that thing a year ago. The value growth increased up to 21% in January, February this year, although there was the price cut impact.
13:36 Next slide, please. The last but not least slide shows the performance of Opsys. Opsys is the first in-class match inhibitor and was launched in July 2021 by our commercial partner, AstraZeneca in China. Around 1,900 new patients were treated in the second half of this year, of last year, with about 60 million US dollars. There are about 13,000 new patients per year with MADS exon 14 skipping for lung small cell lung cancer. But even more importantly, There are over 100,000 med-driven patients in China across all indications.
14:24 So, seven registration studies are already ongoing in China to address these patients in lung, kidney, and gastric cancers. AstraZeneca is a strong commercial partner. It has well-established and extensive commercial platform on lung cancer business.
14:47 There are a lot of synergies between Opsys and AstraZeneca's other non-cancer products.
14:54 We can say Opsys also had a good start in the first two months of this year with $7.4 million in market sales. So overall, we have had a very good year in 2021 and are off to a strong start in 2022. We've had this momentum to continue to go from stress to stress as our commercial team continues to build over the balance of 2022. Thank you.
15:28 Thanks, Chin Hung. So now we'll hand it over to Weiguo and Marek to take us through the discovery and development programs. Weiguo, Marek?
15:43 You may be on mute. Sure, I was. Okay, good evening, good morning. Merrick and I will give you an update on the pipeline. Next slide, please. So 2021 was a busy year, a year with significant progress on our pipeline, highlighted by NDA approvals for sablatinib and surafetinib in China, NDA MAA submissions for surafetinib in the U.S. and EU, and, at the same time, progressing our second wave of compounds, M. disalisib and Savliplanib, into registration studies in China. Next slide. Well, behind the initial approval of Savlitinib in China, together with our partner, AstraZeneca, we are now shaping a very strong lifecycle management strategy with seven studies with a registration potential.
16:42 across lung, kidney, and gastric cancers. Next. Three of these studies are in EGFR mutant non-small cell lung cancer with MET amplification or overexpression using Tigriso-Salvo combo supported by POC data from Tatin, Orchard, and the ongoing Savannah studies.
17:07 Next slide.
17:09 The SIMETA study is a global phase three in MET-driven PRCC supported by strong data from the CLPSO study in combination with MFINZI. To date, PRCC patients have a poor prognosis and very limited treatment options. Moving to serofetin. Let me first ask my colleague, Dr. Merrick Kanya, head of HutchMed International, to give you an update on the global activities.
17:41 Yes, hi, everyone, Marek. On this rule of heart and of arm, we spent really majority of last year progressing our regulatory process in addition to conducting our combination studies with a number of combination partners, including PD-1 with Beijing. As you can see on this slide, summarizing our package for regulatory submissions across US, EMA, and in the near future, PMDA in Japan. We progress this package through a regulatory process. Just as a reminder, this package consists of two positive phase three studies conducted in China, supported by a robust package of US patients from US studies. As Christian alluded at the beginning, we are in the late phase review process in the U.S.
18:38 in pending some remaining inspections in the clinical side as well as mandatory inspection on the manufacturing side. On EMA side, we passed 120-day assessment moving to late phase review process. Next slide, please. While we are progressing our review process, we also, as Christian said, are aggressively preparing for a potential launch, building a very capable medical affairs team, as well as a very strong commercial team, currently 54 FTEs, and as long as we're before strong efforts led by Tom House.
19:24 Next slide, please.
19:30 Life Cycle Management Program for Sufentanil is currently focused on PD-1 combinations. These are toripalimab in China and tizolizumab globally. Based on the encouraging POC Phase II data, we initiated Phase III, the Satori-01 study in second-line neuroendocrine carcinoma. and we are preparing to initiate another phase three in second line esophageal cancer later this year. Other indications will be considered if more mature data will support. Now moving to fluquintinib. Next slide. Back to Merrick.
20:14 Yeah, let me quickly summarize a huge effort in 2021, a progressing program, which in addition to conducting our combination studies with also PD-1 combinations, our majority of effort was focusing on a successful execution of FRESCO II global study. As a reminder, this truly first phase three global study conducted in 14 countries. across 160 sites. I'm pleased to share that as of December, we reached full enrollment, and it just happened in 15 months. So despite of pandemic limitations, it was huge effort on teams, and we are grateful for physicians and patients willing to join this study.
21:02 This really highlights high unmet medical needs, which was assumed before starting this study, but also confirmed and gave us high confidence This study will complement our robust international package, which will be based on our upcoming NDA, MAA, and PMDA submissions. Just an important statement to make, this package was fully aligned with U.S. FDA and EMA through scientific consultation, as well as participation of Japan will assure us Our group starts with PMD submission. Next slide, please.
21:46 In China, we continue to expand lifecycle management programs for flu quentinib. The Frutiga study in second-line gastric cancer in combination with paclitaxel is expected to complete enrollment in second half 2022 and top-line results next year. Combination with the PD-1 inhibitor, Syntilimab, currently second-line endometrial cancer is already in registration study with HCC and RCC registration studies to follow during 2022. Moving on to our second wave compounds, Mdizilisib, the PI3G Delta inhibitor, and Solvoplanib, the SYK inhibitor, both with applications for hematological malignancies.
22:34 Next. Speaking of the hematologic malignancies, we are building a very strong portfolio. To date, six compounds are already in clinics, with several more in discovery. Together, the portfolio provides a broad coverage of three subtypes, lymphoma, leukemia, and multiple myeloma, with a diverse types of MOAs, a strong potential for combination, The two lead compounds M. diselisib and Solvalep planet progressing to registration studies in China and making good progress as well in global studies.
23:17 Next slide.
23:19 The China multi-cohort Phase 1b study continues to enroll in MCL, CLL, and PTCL. Follicular and marginal zone have moved into Phase 2 registration studies last year. Based on the favorable efficacy and safety profile data in follicular published at ESMO 2021, China CDE granted amygdala-listed breakthrough therapy designation for follicular. We expect to complete enrollment for both indications this year and potential NDA submissions during 2023. Additional indications will be considered for registration studies if data support.
24:04 Several exploratory studies, including combination with taser metastat, are preparing to start this year. Next slide. Back to Marek.
24:15 Yeah, on the global side, we are conducting parallel development for undeveloped, and based on our initial promising results in the early phase of our development, we extended significantly our ongoing study to more than 200 patients. and other several cohorts, as you can see. We believe in the second half of the year we'll be in a very good position to not only having a more robust data set, but also longer follow-up, which will inform other next phase development decisions. At the same time, we're also embarking on a combination status as we speak with several potential combination partners.
25:00 Next slide, please.
25:03 Continue on to our second inhibitor, Sovliplanid or HMPO523. In addition to lymphoma, we completed a phase one slash two study in ITP last year. SYK is a validated target for ITP. As you know, Fos-tometinib was approved in 2018. Sovla is a much more selective SYK inhibitor and demonstrated a favorable safety profile with much improved GI and Hypertension Safety Profile. The level of efficacy seen in this phase one slash two study was also very promising. ORR 80% and durable ORR 40%, LBI with small sample sizes.
25:49 Based on the favorable efficacy and safety, CDE granted sublip planet breakthrough therapy designation for ITP. The phase three study is now ongoing. We expect to complete enrollment by end of 2022 and top-line results in 2023. Next slide.
26:10 On the global side for sublet lineage, as you can see, we are conducting really parallel development as well, and this extension cohort study in lymphoma is conducting as we speak. We hope to report more data by end of the year, which will inform our next phase development in lymphoma. At the same time, we are preparing IND for our nonmalignant indication in ITP, again, as Weiguo mentioned, based on promising signals from our China study. So, again, this part will be parallel development. Next slide, please.
26:51 Okay, just a quick update on TazMetastat. TazMetastat is a first-in-class EZH2 inhibitor approved in the U.S. We believe EZH2 is an important target with potential for both solid and blood tumors. Last year, we entered into a collaboration with Epizyme, and again, Rights for Greater China. Obviously, our top priority is to bring it to registration in China quickly. Currently, the bridging study, the bridging study IND in follicular has been cleared, and the study is ready to go. A second registration study, the global Symphony 1, In second-line follicular, we'll be starting off shortly as well.
27:36 In addition, we are interested in exploring a broad range of indications, including in combinations with M. desalicib, fluquintinib, and serofatinib. Globally, we are also in discussion with Epizyme to potentially explore a combination with M. desalicib in lymphoma. Next slide. To sum it up, We are expanding our registration studies with our late-stage compounds, both in China and globally. We anticipate this to continue with more compounds reaching registration and approvals. Next slide. At the same time, our portfolio continues to grow. Four new compounds entered the clinics recently.
28:21 Our goal is to build a pipeline that can provide a good coverage of various tumor types. with diverse MOS that allow science-based combinations of our products to further improve efficacy and maximize the value of our products. Next.
28:42 Great. Thank you, Weiguo. Thank you, Marek. Now we'll hand it over to Johnny Cheng, our CFO, to cover on a high level the financial results that were published today. Johnny?
28:55 Okay, thank you, Christian. So, next slide. Okay, we have a strong balance sheet end of last year with cash resources over $1 billion contributed by cash proceeds from various sources. The IPO, the pipe, and the divestment of our non-core OTC business. Moving on to our operating results in the next slide. Group revenues up more than 50% to over $350 million. The oncology revenue was in line with our guidance, approximately four times of 2020 revenues. Our R&D investment up over 70% to around $300 million. Investment in US and EU have increased significantly and is now at the scale similar to China. The divestment of the OTC business together with the income from the other ventures have helped to offset the cost of the R&D investment. As a result, the overall net loss of the group was $195 million.
30:01 Next slide, please. So on this slide, we can see there are still a lot of value within our other ventures. Looking at the high level, those businesses have delivered over half a billion of net income in the last 20 years. So if we divest further the non-core business, it can help to fund our R&D investment in oncology. Moving on to the next slide. Well, you all heard from Chen Hong talk about the commercial progress that's been made and the momentum that continues into this year. We also see strong initial results in January and February. So as a result, our guidance for 2022 is 160 to 190 million revenues from the oncology business.
30:48 This is China only. So we will incorporate the global revenues in due course When we see the approval coming outside of China. I will now pass to Karen.
31:00 Thank you, Johnny. And next slide, please. We're building a world-class leadership team at HutchMed in line with our ambition to be a global, innovative oncology biopharma company operating to international standards. What's really notable about our team of leaders is their long tenure and their track records. at HutchMed, but also in other major multinational pharmaceutical companies. Tom Held, our US commercial head, and Selina Zhang, who joined us recently as our new head of global HR, and myself as the chief operating officer, have all joined more recently to fill in new roles in the company. And actually, there are many more highly experienced leaders that have joined us beyond the few that you can see in this white box on the slide.
31:46 Next slide, please. We've doubled the number of people in the oncology team in the last two years and we've got plans to grow further. We currently have 1,500 people and last year we added more particularly in clinical and regulatory so that we can run our China clinical trial programs with an in-house team for better speed and quality as well as building out our international clinical and regulatory team to ensure we can run truly global development programs. As you heard before, we've been expanding our oncology commercial team, and at the end of last year, we had 25 people in U.S. commercial. It's now expanded to over 50 people in U.S. medical and commercial in anticipation of the launch of serafatinib this year.
32:34 Next slide, please. We've had clear success with our in-house R&D pipeline, as evidenced by the three innovative medicine approvals in China. But scientific partnerships are also very important to us. From a business development perspective, we're engaged in four key activities. Firstly, we have long-term strategic partnerships with multinational pharmaceutical companies such as AstraZeneca and Eli Lilly. Secondly, pipeline synergy collaborations as we really seek out the best novel combinations, for example, with Epizyme, Junxue, InnoVent, and Beijing. We're also looking to partnerships to increase our bandwidth and finally to gain new capabilities in oncology. For example, in the biologics area, potentially through strategic acquisitions.
33:26 Next slide, please. We have a clear strategy from a geographical perspective.
33:34 In the largest two markets, the US and China, we will launch with our in-house teams whilst partnering out elsewhere. We have the cash and the resources to be able to commercialize ourselves in China and the U.S., which makes sense as we can retain the maximum economic value from our innovations. We already have a strong commercial track record in China, and our U.S. team is moving forward now with seven clinical stage assets, whilst also setting up our serofasinib launch team. For the three late stage products in the international team, We have clear registration plans in place for the US, EU, and Japan with clinical studies underway, and we have the capability to self-develop in those regions.
34:19 However, for commercialization in Europe, Japan, and the rest of the world, we recognize the complexity with more than 100 different countries, each requiring in-depth local knowledge to be successful. And so we've chosen to look for strategic commercial partners outside the US and China, starting with surafatinib and frequentinib this year. I'd now like to hand over to Weiguo.
34:45 Thank you, Karen. Next slide, yeah. So a quick update on the upcoming events in China. We expect 2022 a year of work with so many studies ongoing. and 2023, a year of results and potential regulatory submissions. Obviously, we will be publishing scientific data along the year. Next slide. Globally, 2022 will be a transformative year with important milestones to hit, including potential through FATNIP approval and launch and through Quintinib with FRASCO2 to read out and potentially file.
35:33 Next slide. To conclude, we expect the momentum to continue in 2022. China commercial will continue to grow and the U.S. set to start. Development programs continue to expand with potentially multiple NDAs lined up for the coming years. And our organization is set to grow to support the execution of our goals in the next few years. So 2021 was a busy and fulfilling year, and we expect 2022 to be equally busy and exciting. Next slide. Thank you, and I think we are ready now to take questions. Thank you. We will now begin the question and answer session.
36:21 All your participants with questions to pose, please press 01 on your telephone keypad, and you will be placed in the queue. To cancel the queue, please press 02. Once again, 01 on your telephone keypad now. Our first question comes from the line of Alex Tranam from Bank of America. Please go ahead.
36:45 Hey, everyone. Thanks for taking our questions. And Christian, wanted to offer our congratulations on your move. Obviously, quite a legacy you leave behind at HutchMed. Two questions from us. First, could you maybe talk about choosing toripalamab for the SIRTORI2 study versus some of the other PD1s such as tezolizumab? Is there anything emerging from the clinical data that would suggest that these assets synergize differently with Sulanda or any of your other assets? And as a follow-up to that, when you think about the combination strategies going forward, How much of your approach will be on top of the approved therapies like TD1s versus rational combinations in-house together with some of your earlier stage assets? And then secondly, could you talk a bit about what led to declining the NRDL inclusion for SAVO? I'm guessing this was about the balance of access, price, and concessions, but any color on your thoughts or astros would be great.
37:42 Thanks.
37:45 Maybe Weiguo, I think during the Q&A, Weiguo will lead it. But thank you, Alex, for your kind words. And maybe Weiguo handles the PD-1 questions, and I can maybe give a couple of comments on several itinerant RDL.
38:01 Yeah, sure. So yeah, thanks for the question, Alex. Satori-02 is the registration study In esophageal cancer being planned, and we anticipate the start sometime this year. Now, the combination with TSLA is actually in exploratory stage. Maybe Merrick can give you some more details.
38:29 Yeah, Alex, thanks for the question. You know, we didn't go into details, but both across the frequency and We have multi-cohort combination studies going on with this lab. We hope by end of the year we'll be in position of formulating some good product concept data across several cohorts. We have colorectal, we have small cells. Ned, and so on. So we'll be definitely focusing very eagerly on the signals from those studies. That's a good question. From a US perspective, obviously, that's our first priority.
39:14 Thanks, Meric. With regard to your second question on our preference for combinations, approved versus our own novel drugs, The PD-1s are really a window of opportunity that we pursued and really generated very promising data that now resulted in multiple registration studies. But going forward, obviously, we would love to combine with our own products in our pipeline and really to address strong medical needs Obviously, all these combos will be science-based as I was walking through our pipeline chart.
40:07 Our goal is really to design and build a pipeline with diverse MOA that can cover the tumor types and that offers highest potential for science-based I think going forward you will see a lot more such combinations. Maybe Christian can touch on NRDL for SABO.
40:33 Thanks. Yeah, it was a tough decision. AstraZeneca and Hachmed agreed our strategy going into the negotiations for SABO. The gap was just too wide. The regulatory authorities wanted a deeper discount than we were willing to accept. One of the reasons that we didn't accept it is because Savalitamib is a first-in-class asset in China. We're the only selective MET inhibitor in China. So until such time as that changes, I think we're happy to go out and self-pay with big patient access programs to help Those lower income patients access the drug. My sense is that from the competition standpoint, unlikely to be anything coming to market anytime soon.
41:26 So I imagine we'll go back to the discussions with the regulatory authorities for the NRBL discussion this year. And we'll go into it with an open mind, but it will be dependent on the competitive environment. and a reasonable discount versus an excessive discount.
41:46 Got it. Makes sense. Thank you. The next question comes from the line of Rajen Sharma from Deutsche Bank. Please go ahead.
41:57 Hi. Thanks for the questions and Christian, congratulations on your time at HutchMed and best of luck for the future. My first question actually relates to the change in CEO. And just, you mentioned that it was something that you'd informed the board about five months ago. So just wondering why there's the kind of immediate change in CEO as of tomorrow and why there's no kind of longer transition period. Maybe I'll follow up with a second one afterwards.
42:31 Yeah, thanks, Rajen. I'll answer that, Weiguo. None of these things happen overnight. I've been away from my home for 34 years. As I said, I spent 27 years in China. I'm not sure there are too many Western executives that have spent 27 years in China. And as my family and my children have been growing up, it's been in the back of my mind. But I have to say, The move of my entire family to the UK just for their education, that really was the event that sort of pushed me to the point of realizing staying in Hong Kong and Shanghai for myself was not sustainable.
43:17 So yeah, we approached the nominations committee and the board in September, or I did, And we have an ongoing process, but we just sort of escalated the intensity of that process. It does seem, I'm sure, to everybody that hears this news today as quite a surprise, but obviously it's a sensitive matter that we couldn't signal to the market until we were ready. As we worked through as a board and concluded that Weiguo was the head and shoulders the best candidate for the succession, we've now come with this as quickly as we could. The reason for no extended transition is we feel that, first of all, you don't want to have the old CEO hanging around.
44:09 It's even hard enough in an analyst school today, right? You certainly don't want it in the long term. But Weiguo has been deeply involved in all aspects of the business over the last 16 years. There's no need for a transition, as it were, other than in my role as a strategic advisor to be there for Weiguo, to help him in any way I can with the areas that I've been managing independently over the last few years, and also to help the board and Simon and the Hutchison group to... You know, to keep the momentum going. So I'll be there as a strategic advisor. And as a result, there's no need for some sort of extended transition.
44:54 Hopefully that answers your question.
44:57 Yeah, that's helpful. Thank you. And then just maybe one on operations and on the parchment side of things. Just, you know, you flagged in the release that You would look at obviously non-core asset divestments as a potential for future financing, but then also potentially a second or fourth listing in Shanghai. So could you just perhaps talk about your preference for either of those? And if you do choose to go for a Shanghai listing, would that mean that you would be list from another exchange?
45:37 Maybe I'll ask Simon Toh to answer that question, maybe Johnny to supplement. Weiguo, if that makes sense to you? Yep, absolutely. I was going to suggest, yep. Okay, thank you. This is Simon Toh here. Yes, as you know, we divested of the Bayi Nissan, you know, company, and it was a very good, you know, return for our investment in that company. We, of course, have this other TCM business in Shanghai, you know, the one that is what we call SHPL, but, you know, it's called the 社商保診丸, you know, which is a cardiovascular prescription medicine. And this is a very successful company.
46:28 And a lot of people wanting to buy this asset. And we, of course, you know, we feel that we get an offer that is Weiguo Su, Xinhui Hu, Charles George Rupert Nixon, Selina Zhang, Chig Fung Cheng I think we will continue to discuss and explore with the interested parties.
47:30 Our chairman Mr. To said that this SHPL is a very attractive business so there are many parties who are interested and so we will be very selective and as far as the listing in Shanghai I think we understand the process has been extended previously but now it seems that the authorities in China have been able to speed up the reviewing process so we will again Go back and reveal the plan, and then if the timing is right, then we will initiate some of this initiative that we have looked into earlier.
48:13 Okay, thank you very much. The next question comes from the line of Louis Chan from Cantor Fitzgerald. Please go ahead.
48:28 Thank you for taking my questions. And Christian, thank you for all your contributions to HutchMed, and good luck with all your future endeavors. So my questions are as follows. Can you help us think about the global sales potential of your oncology and immunology portfolio and how you plan to get there? And then on the cash balance, you have a very strong cash balance. What are your capital allocation priorities? And then the last question I have is, how should we think about the trajectory of the U.S. launch of surafatinib What kind of sales should we expect to see this year and what is the U.S. sales potential of this drug? Thank you.
49:05 Okay, on the global sales, I'll ask Merrick and Christian perhaps to take the question.
49:17 Yeah, thank you, Weiguo. So, Luis, out of this year's sales potential, we're not going to speculate on numbers. Everything depends on the timing for approval, and as you observe, dynamics with pandemic-related scheduling and PADUFA changes, you know, we're not going to speculate when it will happen. We're still pending some inspections, so that all depends. Our team will be ready to maximize our launch readiness and commercial activity post-launch, and we are confident with our profile. This will be a good place in the setting. So you can obviously do your modeling in an appropriate way, but we feel very confident. Overall, your second or your third part of broader portfolio performance, As you've seen, we're putting really robust efforts in a global development to maximize our global future commercial potential.
50:16 Obviously, starting from patient in mind, robust clinical trials and bringing the stations representing multinational, you know, reality of clinical practice. You know, with ProQuentinib, we believe this differentiating profile has, you know, plenty of space to grow in third-line class. Colorectal setting, and we feel very confident, you know, of the pending top-line results of CESCO-2. Again, this space is highly underutilized from approved agents, perspective on 25% of agents approved in this setting as it renews everything as the kitchen sink. So, for Quentin, we'll have plenty of space to grow there.
51:05 On the broader portfolio, obviously, we'll be led by science and to maximize our positioning in the respective settings, focusing really on bringing clinical benefits, and we believe that will lead to the results of commercial success as well. I will stop here, Christian, if you want to add something.
51:26 Yeah, Luis, thanks, Mario. It's a good question. I think, you know, we provide in the appendices to our corporate presentation Quite detailed analysis of the global patient populations and the indications we're going after for frequentinib and surafatinib. I think if you're modeling it, you can just assume the levels of pricing that you would expect for these targeted, selective targeted therapies in oncology. Obviously Proquintinib and Surofatinib have many hundreds of millions of dollars of global potential outside of China and inside of China as well. So we'd obviously hope that both of these drugs become billion-dollar drugs. That's what our hope is.
52:13 On the capital allocation, you can see it. Johnny shared with you the financial results from this year where the investment in R&D Thank you. Thank you very much. Based on the science, based on the clinical data, and as we see exciting clinical data come forward, I'm sure we'll be allocating aggressively.
53:03 Weiguo, any thoughts or comments on that?
53:07 I think in general, you know, obviously supporting R&D activities and expanding our manufacturing capacity and ultimately also building our organization and others to support our goals, particularly on the globalization side. So I think these would be certainly our top priorities. Moving to the third question with regard to the trajectory of the US launch of serifatinib, I think Merrick can probably shed some light on that.
53:46 Well, I can kind of address that, you know, depending on the timing of approval and obviously our strong positioning, a few factors depend on the final label and the timing of start of launch. So, you know, RestoSure will be very aggressively positioned to maximize our six Six months, first six months of launch trajectory, which is usually predictive of your overall success. And again, similar to colorectal, only less than 10% of patients are treated currently with targeted agents. So again, psilopatin profile has plenty of space to play.
54:35 Thank you. Good. The next question comes from the line of Yang Huang from Credit Suisse. Please go ahead.
54:47 Thank you. First of all, I'd like to say sorry to see you leave, Christian. You have been doing great work for the company. And also, congratulations to be going to become the CEO of the company. Wish you the best. And my question will be, Thank you very much. Thank you very much. In the recent days, I have seen some career companies, when they did some virtual inspection, it seemed to be some problem and they just want to get a color on the inspection side. And then lastly, if we got approved in the U.S., what could be the label?
56:01 We'll say second line, third line, or how exactly would we expect the label to be? Thanks.
56:11 Thank you. Michael, do you want to address it?
56:15 Yes, go ahead.
56:18 So, thank you for your question. So, you know, regarding your question number one, our ongoing review, obviously, I'm not going to speculate about outcomes nor sharing details of the review, but As you know well, a regulatory review process is long, complex, and robust. You know, sponsor has a role to play, and regulatory agencies have a very important role to play. And this process needs to go through full completion. There are multiple steps of engaging very collaboratively with the agency, answering many, many questions. So, you know, that's what I can say. There's still definitely a few months to go through.
57:06 Regarding your question about the inspections, from FDA perspective, FDA does not like virtual inspections, so I think that's the reality of today. As you've seen across a number of sponsors and indications and applications, SBA has been in the backlog of inspection issues, including not just China-related, but also domestic in the U.S. due to COVID limitations. So you've seen trends that SBA stopped even reacting to PADUFA, but they go through their workloads. So we do expect that whenever possible, those physical inspections will have to happen. And obviously, we hope that the regulations, the limitations in China to travel and move will be limited and allow those inspections to happen.
58:10 A manufacturing inspection is a mandatory process for FD to complete. So obviously, we are ready on both grounds. whenever FDA issues our notifications. Your last question about labeling, you know, NET space is not really line specific. So, you know, we indicated in prior information, our label is in advance both NET and EP-NET and EP-NET and P-NET. So that's our ongoing review labeling. We will be receiving label and we'll be let labeling discussions pending. So we're not there yet. But that was our strategic aim and we continue to be there based on both a standard P and a standard EP study.
59:08 I hope this answers your question.
59:11 Thanks, Marek.
59:15 Okay, if I may, a quick follow-up. So also in your presentation, we showed when looking at the prior therapy, right, the China phase 3 data still shows some difference with U.S. bridging study, right? For example, if we look at prior MRL limits used in China, the percentage is very low, and in U.S. bridging study, it's very high, close to 100%. Was that Did this indicate some kind of standard of care difference between the U.S. and China?
59:53 Well, as we said, standard of care is broadly similar. Obviously, there are some differences in the timing of approvals in China at the time of the conduct of the summit studies, you know, limited access to targeted agents at some point and the timing of approval. So, you know, when you look at the historical Thank you very much. So yeah, you cannot compare one to one, you know, between a phase three study conducted historically with the B4 and the highly refractory population in the U.S., in the U.S. phase one study.
1:01:05 Okay. Okay. Thank you.
1:01:06 Even, you know, with the refractory results, you see, you know, quite impressive, you know, clinical benefits in this highly pretreated population. That's what encourages us. That's what drove us to actually in the US and Europe.
1:01:28 Thanks. You're welcome. The next question comes from the line of Qi Huan from Jefferies. Please go ahead.
1:01:42 Hi, this is Qi Huan at Jefferies. I'm dialing on behalf of Kelly Shi. Congratulations on the great year. I just have two quick questions. Number one, I think in January for Quintinib showed a great data in Phase 1 metastatic colorectal cancer trial. I just want to understand whether the trial data will have any impact on the timeline of your FRASCO2 trial and also the maybe subsequent potential filing for NDA. And my second question is your commercial buildup in the U.S. I understand your China commercial team has progressed very rapidly. Looking at the U.S. personnel on slide 37, you showed the 25 people in the commercial team in the U.S. Could you share your plan for your U.S. commercial buildup maybe this year and next year?
1:02:37 Thank you. Yeah, Merrick, you...
1:02:42 Yeah, so first question about the continuum data. So now, overall, we are very encouraged by the results in our phase one study, both in cohort B and C, as you saw on the slide, which is consistent, again, mimicking almost like fresco study population and the other cohorts mimicking fresco 2 populations. To answer your question directly, no, it's not going to change our, obviously, timing or trajectory of our ongoing effort. As I said, Presco 2 completed enrollment. It's pending maturity and results. The Presco 2 study event-driven overall survival. We are expecting readout of that study in the second half of the year.
1:03:30 Both phase one study, which you're referring to, Fresco study completed in China led to approval in China, Fresco 2 will be the entire package in addition to many other supporting studies. So what this phase one study is giving us really confidence and consistency across different settings and also confirms our assumptions in our Fresco 2 study, which is very encouraging. To answer your question about commercial deals, we are in a very active launch readiness mode. Actually, cross-functionally, both commercial and medical affairs teams are working as we speak very hard, and we're building up.
1:04:16 The 25 was actually, as of last year, currently in a combined headcount, as I showed, with 54 well-being AP Plus Headcount. Obviously, this build will continue, will continue to expand with our frequency new top line results. So the beauty and efficiency we have here is we are operating within GI oncologist-based meds as well as future colorectal. And there is number of efficiency and with the current existing A very strong team on both commercial and medical at first sight, which will give us great trajectory for expansion based on our decisions in the second half of the year.
1:05:02 We feel very strongly and positive, confident that our size of organization will be as much in parity with the needs of highly concentrated, you know, coverage in academic centers, but also ready to Interact with health professionals in the community center who treat MEDS. I hope this answers your question. The next question comes from the line of Mike Mitchell from PennU Gordon. Please go ahead.
1:05:48 Thanks. Hi, everyone. Thanks for taking my questions. But first, it'll be a shame to see you go, Christian. Congratulations on everything you achieved with HutchMed, and also congratulations to Weiguo for assuming the leadership role. I just wondered on that point, given that both CEO and CSO roles are going to be taken on by you, Weiguo, are there any organizational changes that have been made in R&D specifically to further support the CSO role? I mean, clearly it's been a dedicated sole responsibility for Weiguo to date. I just wondered how that will potentially change organizationally.
1:06:21 Well, thanks for the question. We are actively evaluating several options, both internally and externally, with regard to the CSO role, and I think there will be organization change in the future.
1:06:42 Understood. Okay. No, that's great. Thanks, Marco. I think I'll read between the lines there. I just wanted to follow on from Rajan's question, actually. I'm just wondering what the optimal global capital market's presence looks like for HatchMED. I'm just thinking about the proposed Shanghai listing. Given the listings already in the UK, US, and Hong Kong, is supporting four global listings a realistic expectation on your side over the future?
1:07:07 Maybe I could say something on that one. Yeah, and I'll also let Simon and Johnny mention as well, but I think You know, three listings is a lot. Obviously, we've mentioned during this call that we are evaluating other opportunities as well. I think it's not realistic to go higher than three listings, but I'll hand it over to Johnny and Simon to say a couple of things. Yep.
1:07:42 Johnny?
1:07:45 Oh, yes. Johnny, Simon is here.
1:07:49 Maybe you go first. Yeah, Mr. To, sorry, you go first.
1:07:53 Yes, it's no, well, at the moment, you know, we don't really see any urgency to apply for Shanghai listing. I was in Shanghai recently, you know, and went to the stock exchange. They did mention that, yeah, you know, we probably don't like to see for listing, you know, but At the moment, you know, we have plenty of cash. We have also alternative financing, you know, possibilities, non-dilutive financing possibilities. So there's no real urgency, you know, that we must go and get a Shanghai listing. Of course, you know, we will look at which is the best for the shareholders, you know. So, yeah, that's my answer at the moment.
1:08:43 John, do you want to say something?
1:08:46 I think this non-dilutive financing is probably a higher priority for us to look into. The run rate in terms of our cash balance is more than two years, which is average for all biotech companies and which is healthy for us. And with also our These are other ventures that we talk about. Potentially, if we can find a good buyer for that, I think that is something that we will focus a little bit more resources on. And for Shanghai listing, like Mrs. To just mentioned, I think we will continue to evaluate and we will not eliminate that possibility, but it is not an urgent matter for us.
1:09:38 Understood. That's great.
1:09:40 Thanks for your responses there and congratulations once again.
1:09:44 Thank you. We're now going to take the last two questions. And the next question comes from the line of John Newman from Canaccord. Please go ahead.
1:09:59 Hi, good morning. Thanks for taking my question. I also wanted to add my congratulations to you, Christian. You truly built one of the leading biotechnology companies in China. So congrats to yourself and obviously to the whole team. I just had one quick question really on the SICK inhibitor. Just curious if you could talk a little bit more about the timeline for global development. And the reason I ask is we obviously have a few SICK inhibitors improved in the United States, but your asset has a very interesting safety profile as well as efficacy. So curious about the timeline for global development. Thanks.
1:10:39 Yeah, I'll first give you my thoughts and Mary can chime in as well. So we are all very excited about the proof of concept data. Now China is in phase three. We are considering the US and the global development activities for the sick inhibitor. And we believe the data is very, very competitive. Now, obviously, with regard to the timeline, operationally, we are mobilizing. Maybe, Marek, you can chime in and provide some more details.
1:11:17 Yeah, thanks, Weiguo. So, John, you know, as Weiguo said, we were very encouraged by the profile, and we believe it can really stand out. Having said that, you know, we are aggressively focusing on the execution of the expansion cohorts This study was a little bit impacted by our COVID limitations and slows down in phase one. So now we are catching up momentum. So in the second half or maybe by late of this year, we'll have our cohort expansion code completed. And we'll be just doing data assessments and where we can take We have to look carefully at our data both in China and U.S.
1:12:04 holistically, but also on a separate, we have some exposure difference, probably from regulatory strategy perspective. We have different dose in U.S. and China. So we'll be having careful look into next phase development, but as you said, we are as encouraged as during trade. At the same time, you know, during Thank you. The last question comes from the line of Matthew Young from CLSA. Please go ahead. Hi. Thanks for taking my question. I just got a quick one for StabilizerNIP.
1:12:55 I understand that the Phase II trial results likely to come by second half this year, and I wonder how we see the probability of that result, if positive, supporting an NDA filing overseas, or is it more likely you'd like to file an NDA after the Phase II trial spectrum? That's my question.
1:13:17 Thanks. Are you talking about Phase II gastric cancer?
1:13:23 No, he's talking about survival.
1:13:25 Okay. Yeah, obviously, Savannah is ongoing and it's still, but we believe the data is very compelling. And it will be actually, certainly warrants discussion with regulatory authorities for potential registration for conditional approval. The data continues to mature and we'll evaluate if it warrants discussion with regulatory authorities. We are all very happy with the level of efficacy and that's why we are working with AstraZeneca to initiate the phase three, the global phase three.
1:14:22 In this patient population. As I mentioned, you know, during my presentation that together with data from Taptan, Orchard, and Savannah, it forms a great base for a strong base for this Cephron study globally. But particularly for the opportunity in China for, I mean, in the U.S. for conditional approval, we think Savannah is very strong. And we're just, you know, following the data very closely as it matures.
1:14:57 Okay, understood. Thank you very much. If there are no further questions from the line, I will hand the session now back to the host.
1:15:11 Well, thank you very much all and for attending the call and look forward to working with you all in the future. Christian, do you have anything else to add? I don't, Weiguo.
1:15:25 Just other than to say thanks, everybody, for your support through the years. And I wish all the very best of luck to Weiguo and the team going forward. And thank you all.
1:15:40 Thank you very much. Thank you. Thanks. Bye-bye.
1:15:47 Thank you. Bye. Thank you. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
Follow HUTCHMED (China) Limited into a list and get an email when it puts out news.
Chief Executive Officer
Senior Vice President, Commercial (China)
Chief Financial Officer
Chief Scientific Officer / CEO-designate
Head of International Development
Chief Operating Officer
Analyst, Bank of America
Analyst, Deutsche Bank
Analyst, Cantor Fitzgerald
Analyst, Credit Suisse
Analyst, Jefferies
Analyst, PennU Gordon
Analyst, CLSA
Analyst, Canaccord